Stoke Therapeutics, Inc. (STOK)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Stoke Therapeutics, Inc. reported revenue of $184.42M, up 404.5% from the prior year. The company ran a net loss, with a net margin of -3.7%. It held $418.43M in total assets against $65.98M in total liabilities.
Key ratios (FY2025)
-11.2%
Operating margin
-3.7%
Net margin
-2.0%
Return on equity
+404.5%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $184.42M | $36.55M | $8.78M | $12.40M | — | — | — | — | — |
| Operating Income | -$20.59M | -$101.37M | -$114.77M | -$104.36M | -$86.06M | -$53.04M | -$35.68M | -$12.78M | — |
| Net Income | -$6.88M | -$88.98M | -$104.70M | -$101.07M | -$85.81M | -$52.24M | -$32.33M | -$12.52M | — |
| EPS (Diluted) | $-0.12 | $-1.65 | $-2.38 | $-2.60 | $-2.34 | — | — | — | — |
| Total Assets | $418.43M | $271.56M | $228.34M | $256.07M | $238.87M | $297.93M | $228.75M | $107.54M | — |
| Total Liabilities | $65.98M | $42.53M | $68.78M | $71.22M | $21.09M | $11.85M | $4.32M | $2.47M | — |
| Shareholders' Equity | $352.46M | $229.02M | $159.56M | $184.85M | $217.78M | $286.08M | $224.43M | $105.07M | -$1.29M |
| Cash & Equivalents | $84.22M | $127.98M | $191.44M | $113.56M | $144.90M | $287.31M | $222.47M | $105.40M | — |
| Operating Cash Flow | $45.59M | -$86.85M | -$81.07M | -$31.87M | -$66.91M | -$42.22M | -$31.05M | -$10.96M | — |
| Capital Expenditures | $670.0K | $203.0K | $1.62M | $3.96M | $1.20M | $1.05M | $1.64M | $935.0K | — |
| Shares Outstanding | 58.92M | 54.03M | 45.92M | 39.44M | 36.90M | 36.58M | 32.86M | 727.4K | — |